Browse > Article

Influence of Simvastatin on Pharmacokinetics/Pharmacodynamics of Aspirin after Oral Co-administration in Healthy Volunteers  

Gu, Nam-Yi (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine andhospital)
Kim, Bo-Hyung (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine andhospital)
Chung, Yong-Ju (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine andhospital)
Lim, Kyoung-Soo (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine andhospital)
Seo, Hyo-Bum (Clinical Research Coordinating Center, Catholic Medical Center)
Yim, Dong-Seok (Department of Pharmacology, College of Medicine, the Catholic University of Korea)
Shin, Sang-Goo (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine andhospital)
Jang, In-Jin (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine andhospital)
Yu, Kyung-Sang (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine andhospital)
Publication Information
Journal of Korean Society for Clinical Pharmacology and Therapeutics / v.19, no.2, 2011 , pp. 73-83 More about this Journal
Abstract
Background: Both aspirin and simvastatin are prescribed as treatments or prevention of cardiovascular diseases. The aim of this study was to investigate the influence of simvastatin on pharmacokinetics and pharmacodynamics of aspirin after oral co-administration in healthy subjects. Methods: Subjects were orally administered aspirin 100 mg for 7 days followed by co-administration of aspirin 100 mg and simvastatin 40 mg for 7 days once daily. A series of blood samples were collected before and till 24hours after drug administration on Day 1 (single-dose of aspirin), Day 7 (multiple-dose of aspirin) and Day 14 (multiple-dose of aspirin and simvastatin). The effects of simvastatin on pharmacokinetics of acetylsalicylic acid and salicylic acid were assessed with the 90 % confidence intervals (CIs) of thegeometric mean ratios (GMRs) of Day 14 over Day 7 for maximum plasma concentration ($C_{max}$) and the area under the concentration-time curve ($AUC_{0-24}$). Pharmacodynamics was assessed with maximal changes of platelet aggregation from baseline. Results: Twenty-fourhealthy men aged 20 to 36 years were enrolled and 23 of them completed the study. GMRs (90 % CIs) of $C_{max}$ and $AUC_{0-24}$ for acetylsalicylic acid were 1.21 (1.04 - 1.42) and 1.28 (1.19 - 1.38), respectively. For salicylic acid, GMRs of $C_{max}$ and $AUC_{0-24}$ were 0.96 (0.91 - 1.00) and 1.00 (0.97 - 1.04), respectively. Maximal changes of platelet aggregation on Day 7 and Day 14 from baseline were not significantly different (p=0.41); $87.5{\pm}8.8$ % and $87.3{\pm}9.2$ %, respectively. Conclusion: Coadministration of simvastatin slightly increased the systemic exposure of acetylsalicylic acid with no changes of systemic exposure of salicylic acid or inhibition of platelet aggregation.
Keywords
Aspirin; Simvastatin; Drug interactions; Pharmacokinetics; Platelet aggregation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Buchanan, MR, Rischke, JA, hirsh J. Aspirin inhibits platelet function independent of the acetylation of cyclo-oxygenase. Thromb Res, 1982;25(5):363-373.   DOI   ScienceOn
2 Lemos SR, Carvalho SJ, Calisto CB, Nogueira JM, Ravara L. Oral anticoagulant therapy. Fundamentals, clinical practice and recommendations. Rev Port Cardiol, 2007;26(7-8):769-788.
3 Sirtori CR. Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors. Pharmacol Res, 1990;22(5):555-563.   DOI   ScienceOn
4 Hebert PR, gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA, 1997;278(4):313-321.   DOI   ScienceOn
5 Kees F, Jehnich D, grobecker H. Simultaneous determination of acetylsalicylic acid and salicylic acid inhuman plasma byhigh-performance liquid chromatography. J Chromatogr B Biomed Appl, 1996;677(1):172-177.   DOI   ScienceOn
6 Hennekens CH, Schneider WR. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. Expert Rev Cardiovasc Ther, 2008;6(1):95-107.   DOI   ScienceOn
7 Nimpf J, Wurmh, KostnergM, Kenner T. Platelet activation in normo- and hyperlipoproteinemias. Basic Res Cardiol, 1986;81(5):437-453.   DOI   ScienceOn
8 Friend M, Vucenik I, Miller M. Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ, 2003;326(7380):82-83.   DOI   ScienceOn
9 Undas A, Siudak Z, Topor-Madry R, Lesniak M, Tracz W. Simvastatin administration reduces thromboxane production in subjects taking aspirin: Links between aspirin resistance and thrombin generation. Int J Cardiol, 2012;154(1):59-64.   DOI   ScienceOn
10 Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronaryheart disease events in men: a cost-utility analysis. Ann Intern Med, 2006;144(5):326-336.   DOI   ScienceOn
11 Jang SB, Lee YJ, Lim LA, Park KM, Kwon BJ, Woo JS, Kim YI, Park MS, Kim KH, Park K. Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin inhealthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. Clin Ther, 2010;32(1):206-216.   DOI   ScienceOn
12 McMahon GP, Kelly MT. Determination of aspirin and salicylic acid inhuman plasma by column-switching liquid chromatography using on-line solid-phase extraction. Anal Chem, 1998;70(2):409-414.   DOI   ScienceOn
13 Zhao JJ, Xie IH, Yang AY, Roadcap BA, Rogers JD. Quantitation of simvastatin and its beta-hydroxy acid inhuman plasma by liquid-liquid cartridge extraction and liquid chromatography/tandem mass spectrometry. J Mass Spectrom, 2000;35(9):1133-1143.   DOI   ScienceOn
14 Yang AY, Sun L, Musson DG, Zhao JJ. Application of a novel ultra-low elution volume 96-well solid-phase extraction method to the LC/MS/MS determination of simvastatin and simvastatin acid inhuman plasma. J Pharm Biomed Anal, 2005;38(3):521-527.   DOI   ScienceOn
15 Kim J, Ahn BJ, Chae HS, han S, Doh K, Choi J, Jun YK, Lee YW, Yim DS. A Population Pharmacokinetic-Pharmacodynamic Model for Simvastatin that Predicts Low-Density Lipoprotein-Cholesterol Reduction in Patients with Primaryhyperlipidaemia. Basic Clin Pharmacol Toxicol, 2011;109(3):156-163.   DOI   ScienceOn
16 Mardikarh, Deo D, Deshpande N, Mardikar M, Ghosh A, Munot K, Steinhubl S, Mukherjee D. Variability in platelet response to a single daily dose of 150 mg enteric coated aspirin in ahigh risk population. J Assoc Physicians India, 2008;56:321-324.
17 Williams FM. Clinical significance of esterases in man. Clin Pharmacokinet, 1985;10(5):392-403.   DOI   ScienceOn
18 Yang F, Bian C, Zhu L, Zhaog,huang Z, Huang M. Effect ofhuman serum albumin on drug metabolism: structural evidence of esterase activity ofhuman serum albumin. J Struct Biol, 2007;157(2):348-355.   DOI   ScienceOn
19 Honma K, Nakamura M, Ishikawa Y. Acetylsalicylate-human serum albumin interaction as studied by NMR spectroscopy-antigenicity-producing mechanism of acetylsalicylic acid. Mol Immunol, 1991;28(1-2):107-113.   DOI   ScienceOn
20 Fukami T, Takahashi S, Nakagawa N, Maruichi T, Nakajima M, Yokoi T. In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs onhuman carboxylesterase activities. Drug Metab Dispos, 2010;38(12):2173-2178.   DOI   ScienceOn
21 Roensch J, Crisby M, Nordberg A, Xiao Y, Zhang LJ ,guan ZZ. Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells. Neurochem Int, 2007;50(6):800-806.   DOI   ScienceOn
22 Bertrand ME, Simoons ML, Fox KA, Wallentin LC,hamm CW, McFadden E, de Feyter PJ, Specchiag, Ruzyllo W. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J, 2000;21(17):1406-1432.   DOI   ScienceOn
23 Van Lith HA, MeijergW,haller M, Beynen AC. Serum pseudocholinesterase activity in rabbits fed simvastatin. Biochem Pharmacol, 1991;41(3):460-461.   DOI   ScienceOn
24 Darvesh S, Martin E, Walsh R, Rockwood K. Differential effects of lipid-lowering agents onhuman cholinesterases. Clin Biochem, 2004;37(1):42-49.   DOI   ScienceOn
25 Muacevic-Kataneca D, Bradamante V, Reinec Z, Sucic M, Poljicanin T, Busljeta I, Metelko Z. Clinical study on the effect of simvastatin on butyrylcholinesterase activity. Arzneimittelforschung, 2005;55(5):271-275.
26 Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD,hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN. ACC/AHAguidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/Americanheart Association task force on practiceguidelines (committee on the management of patients with unstable angina). Circulation, 2000;102(10):1193-1209.   DOI   ScienceOn